FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892938674> ?p ?o ?g. }

• W2892938674 endingPage "321" @default.
• W2892938674 startingPage "312" @default.
• W2892938674 abstract "MicroRNA (miR) sponges containing miR binding sequences constitute a potentially powerful molecular therapeutic strategy. Recently, naturally occurring circular RNAs (circRNAs) were shown to function as efficient miR sponges in cancer cells. We hypothesized that synthetic circRNA sponges could achieve therapeutic loss-of-function targeted against specific miRs. Linear RNA molecules containing miR-21 binding sites were transcribed in vitro; after dephosphorylation and phosphorylation, circularization was achieved using 5′-3′ end-ligation by T4 RNA ligase 1. circRNA stability was assessed using RNase R and fetal bovine serum. Competitive inhibition of miR-21 activity by a synthetic circRNA sponge was assessed using luciferase reporter, cell proliferation, and cell apoptosis assays in three gastric cancer cell lines. circRNA effects on downstream proteins were also delineated by Tandem Mass Tag (TMT) labeling (data available via ProteomeXchange identifier PRIDE: PXD008584), followed by western blotting. We conclude that artificial circRNA sponges resistant to nuclease digestion can be synthesized using simple enzymatic ligation steps. These sponges inhibit cancer cell proliferation and suppress the activity of miR-21 on downstream protein targets, including the cancer protein DAXX. In summary, synthetic circRNA sponges represent a simple, effective, convenient strategy for achieving targeted loss of miR function in vitro, with potential future therapeutic application in human patients. MicroRNA (miR) sponges containing miR binding sequences constitute a potentially powerful molecular therapeutic strategy. Recently, naturally occurring circular RNAs (circRNAs) were shown to function as efficient miR sponges in cancer cells. We hypothesized that synthetic circRNA sponges could achieve therapeutic loss-of-function targeted against specific miRs. Linear RNA molecules containing miR-21 binding sites were transcribed in vitro; after dephosphorylation and phosphorylation, circularization was achieved using 5′-3′ end-ligation by T4 RNA ligase 1. circRNA stability was assessed using RNase R and fetal bovine serum. Competitive inhibition of miR-21 activity by a synthetic circRNA sponge was assessed using luciferase reporter, cell proliferation, and cell apoptosis assays in three gastric cancer cell lines. circRNA effects on downstream proteins were also delineated by Tandem Mass Tag (TMT) labeling (data available via ProteomeXchange identifier PRIDE: PXD008584), followed by western blotting. We conclude that artificial circRNA sponges resistant to nuclease digestion can be synthesized using simple enzymatic ligation steps. These sponges inhibit cancer cell proliferation and suppress the activity of miR-21 on downstream protein targets, including the cancer protein DAXX. In summary, synthetic circRNA sponges represent a simple, effective, convenient strategy for achieving targeted loss of miR function in vitro, with potential future therapeutic application in human patients." @default.
• W2892938674 created "2018-10-05" @default.
• W2892938674 creator A5011476548 @default.
• W2892938674 creator A5015933395 @default.
• W2892938674 creator A5024270187 @default.
• W2892938674 creator A5032028356 @default.
• W2892938674 creator A5033696694 @default.
• W2892938674 creator A5041527259 @default.
• W2892938674 creator A5044138805 @default.
• W2892938674 creator A5044586487 @default.
• W2892938674 creator A5056053058 @default.
• W2892938674 creator A5057923079 @default.
• W2892938674 creator A5081445006 @default.
• W2892938674 creator A5083247969 @default.
• W2892938674 creator A5083409124 @default.
• W2892938674 creator A5088543620 @default.
• W2892938674 date "2018-12-01" @default.
• W2892938674 modified "2023-10-14" @default.
• W2892938674 title "Synthetic Circular RNA Functions as a miR-21 Sponge to Suppress Gastric Carcinoma Cell Proliferation" @default.
• W2892938674 cites W1970760326 @default.
• W2892938674 cites W1971144342 @default.
• W2892938674 cites W1972989638 @default.
• W2892938674 cites W1979285004 @default.
• W2892938674 cites W1985568137 @default.
• W2892938674 cites W1986555537 @default.
• W2892938674 cites W1989773675 @default.
• W2892938674 cites W2012511861 @default.
• W2892938674 cites W2033966391 @default.
• W2892938674 cites W2040776936 @default.
• W2892938674 cites W2056302937 @default.
• W2892938674 cites W2058835062 @default.
• W2892938674 cites W2064165694 @default.
• W2892938674 cites W2074478736 @default.
• W2892938674 cites W2076011658 @default.
• W2892938674 cites W2080391964 @default.
• W2892938674 cites W2088672733 @default.
• W2892938674 cites W2108104027 @default.
• W2892938674 cites W2111990378 @default.
• W2892938674 cites W2114104545 @default.
• W2892938674 cites W2120040038 @default.
• W2892938674 cites W2121626677 @default.
• W2892938674 cites W2131456432 @default.
• W2892938674 cites W2139992910 @default.
• W2892938674 cites W2148287035 @default.
• W2892938674 cites W2159154322 @default.
• W2892938674 cites W2162674813 @default.
• W2892938674 cites W2168750261 @default.
• W2892938674 cites W2219781244 @default.
• W2892938674 cites W2284415752 @default.
• W2892938674 cites W2316171452 @default.
• W2892938674 cites W2561510608 @default.
• W2892938674 cites W2562634188 @default.
• W2892938674 cites W2572693230 @default.
• W2892938674 cites W2586427318 @default.
• W2892938674 cites W2590096890 @default.
• W2892938674 cites W2593315117 @default.
• W2892938674 cites W2605363845 @default.
• W2892938674 cites W2616072553 @default.
• W2892938674 doi "https://doi.org/10.1016/j.omtn.2018.09.010" @default.
• W2892938674 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6197335" @default.
• W2892938674 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30326427" @default.
• W2892938674 hasPublicationYear "2018" @default.
• W2892938674 type Work @default.
• W2892938674 sameAs 2892938674 @default.
• W2892938674 citedByCount "133" @default.
• W2892938674 countsByYear W28929386742019 @default.
• W2892938674 countsByYear W28929386742020 @default.
• W2892938674 countsByYear W28929386742021 @default.
• W2892938674 countsByYear W28929386742022 @default.
• W2892938674 countsByYear W28929386742023 @default.
• W2892938674 crossrefType "journal-article" @default.
• W2892938674 hasAuthorship W2892938674A5011476548 @default.
• W2892938674 hasAuthorship W2892938674A5015933395 @default.
• W2892938674 hasAuthorship W2892938674A5024270187 @default.
• W2892938674 hasAuthorship W2892938674A5032028356 @default.
• W2892938674 hasAuthorship W2892938674A5033696694 @default.
• W2892938674 hasAuthorship W2892938674A5041527259 @default.
• W2892938674 hasAuthorship W2892938674A5044138805 @default.
• W2892938674 hasAuthorship W2892938674A5044586487 @default.
• W2892938674 hasAuthorship W2892938674A5056053058 @default.
• W2892938674 hasAuthorship W2892938674A5057923079 @default.
• W2892938674 hasAuthorship W2892938674A5081445006 @default.
• W2892938674 hasAuthorship W2892938674A5083247969 @default.
• W2892938674 hasAuthorship W2892938674A5083409124 @default.
• W2892938674 hasAuthorship W2892938674A5088543620 @default.
• W2892938674 hasBestOaLocation W28929386741 @default.
• W2892938674 hasConcept C104317684 @default.
• W2892938674 hasConcept C10879258 @default.
• W2892938674 hasConcept C119056186 @default.
• W2892938674 hasConcept C145059251 @default.
• W2892938674 hasConcept C153911025 @default.
• W2892938674 hasConcept C55493867 @default.
• W2892938674 hasConcept C62112901 @default.
• W2892938674 hasConcept C67705224 @default.
• W2892938674 hasConcept C86803240 @default.
• W2892938674 hasConcept C95444343 @default.
• W2892938674 hasConceptScore W2892938674C104317684 @default.
• W2892938674 hasConceptScore W2892938674C10879258 @default.

• next